Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR0012333284
Mon, 30.11.2020
ABIVAX
Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis
Recruitment of 232 patients completed ahead of schedule with minimal impact by the Covid-19 pandemic
Top-line results expected to be available in Q2 2021
Maintenance open label extension Phase 2b study in UC progressing well with 130 patients enrolled and expan [ … ]
Mon, 16.11.2020
ABIVAX
Abivax Receives "Best Technology Award" at the European Mediscience Awards 2020
Recognizes innovative and unique mechanism of action of ABX464, with its antiviral, anti-inflammatory and tissue repair characteristics
In Phase 2b trial in ulcerative colitis, Phase 2a in rheumatoid arthritis, Phase 2b/3 in high-risk Covid-19 patients; pivotal Phase [ … ]
Mon, 02.11.2020
ABIVAX
Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price
PARIS, November 02, 2020 - 2:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases [ … ]
Thu, 29.10.2020
ABIVAX
Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price
Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)
Total financing since June 2020 amounting to EUR 84m, 2/3 non-dilutive (EUR 56m from Bpifrance, Kreos, Soc [ … ]
Tue, 13.10.2020
ABIVAX
Abivax secures EUR 15m non-dilutive financing from Kreos Capital
EUR 15m straight bonds, with no associated dilution, favorable financial conditions in interest rates and no expected transaction fees
Pre-negotiated EUR 5m additional straight bond tranche to be decided before 2020 year-end
Cash for operations extended until Q2 2021
PARIS, October [ … ]
Wed, 30.09.2020
ABIVAX
Abivax announces the release of its 2020 half-year financial report
PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publicati [ … ]
Thu, 24.09.2020
ABIVAX
Abivax presents first-half 2020 financial results and operations update
ABX464 Phase 2a ulcerative colitis two-year maintenance study results confirm good safety profile and durable efficacy of 50 mg once-daily oral ABX464
77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the [ … ]
Wed, 02.09.2020
ABIVAX
Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
Phase 2a open label maintenance results after second year of treatment confirm good safety profile and durable efficacy of 50mg once-daily oral ABX464
After the second year of continued treatment, 69% of patients were in clinic [ … ]